Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Listed as NCT00000590, this PHASE3 trial focuses on Acquired Immunodeficiency Syndrome and Disease Transmission, Vertical and remains completed. Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), it has been updated 5 times since 1991, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Sep 1991
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.